Aims: Kv1.1 (KCNA1) channels contribute to the control of neuronal excitability and have been associated with epilepsy. Kv1.1 channels can associate with the cytoplasmic Kvβ1 subunit resulting in rapid inactivating A-type currents. We hypothesized that removal of channel inactivation, by modulating Kv1.1/Kvβ1 interaction with a small molecule, would lead to decreased neuronal excitability and anticonvulsant activity.
| INTRODUC TI ON
Voltage-gated potassium channels (Kv) play important roles in the regulation of cellular functions and are involved in the control of cellular excitability in neuronal and cardiac tissues. The different biophysical properties of Kv channels provide a diversity of potassium current activities able to control, for example, the duration and firing frequency of action potentials and the stabilization of membrane potential. 1 Structural investigations indicated that Kv channels assemble as tetramers in the cell membrane 2 and some Kv family members may specifically associate with accessory proteins in the membrane or in the cytoplasmic domains, thus providing a more diverse and and are localized at axonal initial segments and at synaptic terminals where they contribute to the control of action potential firing and neurotransmitter release. [12] [13] [14] [15] The block of Kv1.1 channels by α-dendrotoxin induces tonic firing in central neurons 12 and in vivo Kv1.1 antisense knockdown promotes the broadening of action potentials and reduction in the after-hyperpolarization, 16 suggesting that decreased activity of Kv1.1 channels leads to neuronal hyperexcitability. As a result, deletion of Kv1.1 channels in mice leads to increased neuronal network excitability 17 and translates into ataxia and spontaneous seizure activity. 11 The genetic mutations of KCNA1 have been associated with episodic ataxia type 1 (EA1) 18 and seizure activity in humans. 19, 20 Additional studies indicated a potential role of Kv1.1 in epileptogenesis by demonstrating that overexpression of Kv1.1 in the epileptic focus of epileptic animals translated into a reduced excitability of pyramidal neurons and suppression of epileptiform activity over several weeks. 21 The association of Kv1.1 with the leucine-rich glioma inactivated gene 1 (Lgi1), a protein that has been identified as the causative gene for autosomal dominant lateral temporal lobe epilepsy (ADLTE), provides further evidence for a dysregulation of Kv1.1 function in epilepsy. 22 Indeed, the mutated Lgi1 protein does not prevent Kvβ1 mediated N-type inactivation of Kv1.1 channels, suggesting that sustained inactivation of Kv1.1 may promote epileptic activity. More recent studies also demonstrated that Kv1.1 expression is repressed in an experimental model of poststatus-induced epileptogenesis and confirming that a loss of Kv1.1 activity leads to hyperpolarization of action potential threshold resulting in CA1 pyramidal neuron hyperexcitability. 23 We hypothesized that modulation of the Kv1.1/Kvβ1 protein complex by interfering with the N-type inactivation mechanism would provide a valid approach for the development of novel antiepileptic drugs. 
| Cloning and expression of channel proteins
The human Kv1.1 channel T1 domain (KCNA1; residues 1-160) and the human Kvβ1.1 core domain (KCNAB1; residues 87-419), were cloned into a pcDNA3.3-MCS vector in the presence of a FLAG or a myc tag sequence, respectively. Mutant Kv1.1 channels were generated by PCR site-directed mutagenesis at Genscript (Piscataway, NJ, USA).
For functional expression in HEK293F cells, human Kv1.1, Kvβ1.1 and Kv1.4 (GenBank Accession Number: NM_000217, NM_172160, NM_002233) were cloned into pCDNA3 vectors and transiently transfected into HEK293F suspension cells using 293fectin and cultured for 48 h. The polyA-tailed mRNA transcripts for Kv1.1 and Kvβ1 proteins were synthesized by RD-Biotech (Besançon, France).
| Compounds
Compound A was purchased from Chembridge. Cortisone was purchased from Sigma (Saint-Louis, MO, USA) and dissolved and stored at −20°C in DMSO as a stock solution of 100 mmol/L. 
| Two-electrode voltage clamp (TEVC) recordings in Xenopus oocytes

| Current-clamp recordings in hippocampal neurons
Neuronal sustained repetitive firing (SRF) recordings were performed by whole-cell patch clamp in neurons from hippocampal slices prepared from male Sprague-Dawley rats as previously described. 27 SRF was induced by the repetitive application of 5-sec- 
(v/v). Statistical differences between control group and compound
A-treated group were assessed by using a two-tailed Student's t test (P < 0.05).
| Field potential recordings in hippocampal slices
The high K + -low Ca 2+ model was performed on rat hippocampal slices as previously described. 28 Field potentials (FPs) were evoked upon fim- by using a two-tailed Student's t test (P < 0.05).
| RE SULTS
| Mutations at the Kv1.1/Kvβ1 interface remove channel inactivation
The tetrameric Kv1.1 channel forms a stable complex with its ac- 
| Identification of small molecules that modulate Kv1.1 and Kvβ1 interaction
For the screening of small molecules on the Kv1.1/Kvβ1 complex, we coexpressed the Kv1. 
and acceptor beads and resulting in light emission. The coexpression of the Kv1.1-T1 and Kvβ1 proteins, fused to a Flag tag at the Kv1.1-T1
C-terminus and a myc tag at the Kvβ1 N-terminus, was the only combination generating a strong ALPHA signal ( Figure 2A ). The Kv1.1-T1/Kvβ1 protein complex was previously shown to be disrupted by cortisone, 5 and we verified that cortisone produced a strong con- , n = 7, data not shown) in agreement with previous published data. 5 The Kv1.1 T1 domain is highly conserved among Kv1.x channels and a previous study indicated that compounds that modulate the inactivation of Kv1.1/Kvβ1 channels may also affect the inactivation levels of the closely related Kv1.4 channels. τ slow = 62 ± 29 ms and 73 ± 8 ms (n = 5) for compound and controltreated cells, respectively; P > 0.05, t test) ( Figure 4C ) and had no significant effect on the current-voltage relationship of this channel (P > 0.05, t test) ( Figure 4D ). Cortisone (300 μmol/L) was shown to inhibit inactivation by binding to the Kvβ1 protein 5 and should thus not affect Kv1.4 inactivation currents. We confirmed that cortisone does not modulate inactivation levels of Kv1.4 channels in our experiments (inhibition of steady state inactivation of −0.2 ± 7%, n = 9, data not shown) further supporting its specific mechanism mediated by the Kvβ1 subunit.
| Modulation of Kv1.1/Kvβ1 complex and its effect on neuronal firing
The identification of compound A as a negative modulator of Kv1.1/ Kvβ1 inactivation prompted us to further evaluate its activity in a neuronal system. Based on the findings that Kv1.1 blocking toxins increase neuronal firing 12 and that overexpression of Kv1.1 reduces neuronal excitability, 21, 24 we hypothesized that reducing inactivation of neuronal Kv1.1 channels would lead to decreased neuronal excitability. We decided to study the effects of compound A on the sustained repetitive firing of neuronal action potentials in granule cells of the dentate gyrus, a region that expresses high levels of 
| Effects of compound A on in vitro epileptiform activity
To evaluate the potential of compound A as an anticonvulsant, we perfused hippocampal slices with a high K + -low Ca 2+ ACSF (HKLC)
to induce epileptiform activity and performed extracellular field potential recordings in CA3 area. 28, 33 Evoked responses ( Figure 6A ), obtained through fimbria stimulation, and spontaneous responses ( Figure 6C ) were periodically recorded during 1-hour perfusion under HKLC conditions in a control group of slices (n = 8 slices from 8 rats) and in a group of slices preincubated with 100 μmol/L compound A (n = 8 slices from 4 rats). In the latter group, 100 μmol/L of compound A was also added during HKLC perfusion. At the onset of experiment, input-output responses were recorded in both groups of slices under normal ACSF conditions. Input-output curves illustrated in Figure 6B show that preincubation of slices with compound A produced a nonsignificant reduction in the amplitude of the population spike (PS1) for stimulation intensities >0.2 mA. In both groups of slices, the stimulation threshold for response and the number of PSs evoked during the input-output stimulation protocol were similar.
In control slices, when the perfusion solution was shifted from ACSF to HKLC, the CA3 field potentials, evoked upon constant current fimbrial stimulation, developed an epileptiform activity. As previously described, 33 the amplitude of the PS gradually raised ( Figure 6A ) and the number of evoked repetitive PSs (forming bursts)
were increased within 20-40 minutes after the start of perfusion with HKLC ( Figure 6D ). After 20-minutes perfusion with HKLC, spontaneous bursts were recorded in the CA3 area ( Figure 6C ) and their number increased to a maximal level after ~50 minutes of perfusion ( Figure 6D ). The amplitude of spontaneous bursts also increased during the same period ( Figure 6C ).
In HKLC conditions, the treatment of slices with compound A (100 μmol/L) prevented the increase of PS2 and PS3 amplitudes (Table 1 , Figure 6A ), of evoked burst areas (Table 1) 
| CON CLUS IONS
We verified our initial hypothesis that the perturbation of the The values are given as mean ± SEM, for 8 slices in each group. Significant differences, with respect to the control group, were assessed with a two-tailed t test: 36 inhibits the increase in PS amplitude suggesting a mechanism acting mainly through a desynchronization of the neuronal activity. We propose that targeting the Kv1.1-T1/Kvβ1 protein complex is a valid approach for the development of novel drugs that provide a differentiated mechanism and a potential for improved therapeutic benefits. Based on the observations that Kv1.1 overexpression may affect epileptogenesis, 21 we may speculate that brain penetrant small molecules inhibiting Kv1.1 inactivation could provide a potential for symptomatic treatment and disease modification in epilepsy.
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